New candidates, APVO452 and APVO451, harness proprietary ADAPTIR-FLEXTM design to target prostate and multiple solid tumor cancers by simultaneously engaging…
Collaboration builds upon positive results utilizing Predictive Oncology’s AI platform to identify new indications for existing drugsPITTSBURGH, Sept. 04, 2025…
Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses the Company’s recently announced results from the post hoc analysis of…
SOLANA BEACH, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling…
Dr. Trieu’s prolific career includes multibillion-dollar drug discoveries targeting cancers of the breast, pancreas and non-small cell lung cancer, among…
VANCOUVER, Washington, Sept. 04, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage biotechnology company advancing…
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf…
'The Breast Cancer Dialogues' Available Now Watch First Two Episodes HERE NEW YORK, Sept. 3, 2025 /PRNewswire/ -- SurvivorNet, the nation's leading…
WESTFORD, Mass., Sept. 3, 2025 /PRNewswire/ -- The global surgical robots market is rapidly changing, as advanced technologies converge with…
Exousia Pro aims to develop three new subdivisions and launch new products during the 4th quarter.The market for our new…